https://www.live-feeds.com/feed/as-revmed-preps-for-historic-pancreatic-cancer-launch-questions-linger-on-the-groundContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/as-revmed-preps-for-historic-pancreatic-cancer-launch-questions-linger-on-the-groundhttps://www.live-feeds.com/feed/as-revmed-preps-for-historic-pancreatic-cancer-launch-questions-linger-on-the-ground#u52326Sun, 30 Aug 2026 11:00:08 +0000The FDA has approved daraxonrasib, marketed as RASONQUE, a breakthrough pill developed by RevMed to treat pancreatic cancer. The drug carries a monthly list price of $39,800. While described as a transformative treatment for a deadly disease, the launch faces scrutiny regarding its practical implementation on the ground. The medication is already being used by some patients, including a Philadelphia police officer who stated the treatment gives him hope.Why it mattersPancreatic cancer is characterized as a deadly disease with limited treatment options. This approval marks a new era for care by